Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Grows By 39.6%

BioAtla, Inc. (NASDAQ:BCAB) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 6,612,587 shares, an increase of 39.6% from the January 15th total of 4,737,947 shares. Approximately 11.8% of the company’s shares are sold short. Based on an average daily volume of 2,545,992 shares, the days-to-cover ratio is presently 2.6 days. Based on an average daily volume of 2,545,992 shares, the days-to-cover ratio is presently 2.6 days. Approximately 11.8% of the company’s shares are sold short.

BioAtla Stock Down 8.9%

Shares of NASDAQ:BCAB opened at $0.15 on Monday. BioAtla has a fifty-two week low of $0.14 and a fifty-two week high of $1.43. The stock has a market cap of $9.52 million, a price-to-earnings ratio of -0.13 and a beta of 1.11. The firm’s 50 day moving average price is $0.47 and its 200 day moving average price is $0.59.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts anticipate that BioAtla will post -1.46 EPS for the current year.

Wall Street Analyst Weigh In

BCAB has been the topic of several research analyst reports. Rodman & Renshaw assumed coverage on BioAtla in a report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Investors Weigh In On BioAtla

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sheets Smith Investment Management acquired a new stake in BioAtla during the third quarter worth approximately $46,000. Woodline Partners LP purchased a new stake in BioAtla in the first quarter valued at $26,000. Jane Street Group LLC boosted its stake in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares in the last quarter. Vanguard Group Inc. boosted its stake in BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after acquiring an additional 162,647 shares in the last quarter. Finally, Susquehanna International Group LLP grew its holdings in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.